Solventum (NYSE:SOLV) Issues Quarterly Earnings Results

Key Points

• Solventum reported a quarterly earnings per share of $1.69, exceeding analyst expectations of $1.45 and showing a year-over-year increase from $1.56.
• The company achieved $2.16 billion in revenue, surpassing the forecast of $2.12 billion, with a 3.8% increase from the same quarter last year.
• Analysts have recently raised their price targets for Solventum, with Piper Sandler setting it at $94.00 and Morgan Stanley increasing it to $103.00, reflecting a positive outlook for the stock.

Solventum (NYSE:SOLV - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24, Zacks reports. Solventum had a return on equity of 31.14% and a net margin of 4.52%. The firm had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. During the same quarter last year, the business earned $1.56 EPS. The company's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum updated its FY 2025 guidance to 5.800-5.950 EPS.

Solventum Price Performance

NYSE:SOLV traded up $1.39 during trading hours on Friday, hitting $73.34. The company's stock had a trading volume of 1,758,120 shares, compared to its average volume of 629,965. The stock has a fifty day simple moving average of $74.21 and a 200-day simple moving average of $73.00. The company has a market capitalization of $12.69 billion, a P/E ratio of 33.95, a PEG ratio of 1.88 and a beta of 0.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. Solventum has a twelve month low of $56.69 and a twelve month high of $85.92.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SOLV. Piper Sandler raised their price target on Solventum from $87.00 to $94.00 and gave the stock an "overweight" rating in a research report on Friday. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Wells Fargo & Company raised their price target on Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research report on Friday. KeyCorp began coverage on Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating on the stock. Finally, Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Tuesday, July 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $85.75.

Institutional Trading of Solventum

Several large investors have recently bought and sold shares of the business. United Services Automobile Association acquired a new stake in shares of Solventum during the first quarter valued at about $239,000. Woodline Partners LP boosted its stake in shares of Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company's stock valued at $888,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock valued at $1,268,000 after purchasing an additional 10,425 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.